News Summary

• Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations.
• The company holds a global leadership position in corticosteroid and steroidal-hormone APIs.
• Its revenue primarily comes from international markets, with Europe being a significant contributor.
• Financials show steady revenue and EBITDA growth over recent years.
• Investors with a high-risk appetite may consider this long-term opportunity.
• ET Prime special: Bigger, Better or Both?
• Understanding business to figure out the mystery: Power Grid Corp – Part 1 US bond yield: Will it become a new pain point?
• Bigger or Better: BEL’s biggest shareholder is also its biggest customer – and its rule-maker.